Nektar Therapeutics: Alopecia Update And A Look At The Road Ahead For Rezpeg
Summarize this article with:
Biotech Beast9.01K FollowersFollow5ShareSavePlay(10min)CommentsSummaryNektar Therapeutics's results from REZOLVE-AA, a trial of rezpegaldesleukin in alopecia areata, have failed to stimulate a rally in the stock.Even with concerns about statistical significance in the trial results, the drug does look to have activity in alopecia areata.Further data is coming from the atopic dermatitis study, REZOLVE-AD in Q1 '26, and from REZOLVE-AA in early Q2'26, meaning there are catalysts ahead for NKTR. Gary Yeowell/DigitalVision via Getty Images Nektar Therapeutics (NKTR) is continuing on with development of rezpegaldesleukin, following successful results in atopic dermatitis and this week's results in alopecia areata. I haven't written about NKTR since November 2024, when I This article was written byBiotech Beast9.01K FollowersFollowScientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don't constitute investment advice.Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.